High-throughput proteomics combined with artificial intelligence improves early disease risk prediction, according to a review published in Science Bulletin by Chinese researchers.
Proteomics provides dynamic biological insights beyond genomics
Proteomics studies proteins, the functional molecules that link genes to physiology, offering a real-time view of biological activity that genomics cannot capture.
Genomics provides static genetic information, while proteomics tracks changing biological states shaped by both genetics and environmental factors.
High-throughput technology enables large-scale protein analysis
Recent technological advances allow simultaneous measurement of thousands of proteins in a single sample, enhancing diagnostic accuracy, and speed.
Blood-based proteomics supports large population studies, whereas cerebrospinal fluid analysis offers precise data for neurological conditions like Alzheimer’s and Parkinson’s.
Urine and tissue samples provide disease-specific insights but may face limitations due to variability, technical constraints, or invasiveness.
Proteomics bridges gaps in traditional risk prediction models
Traditional tools such as polygenic risk scores estimate genetic susceptibility but do not account for environmental and lifestyle influences.
Proteomics reflects real-time biological activity, making it valuable for predicting disease risk in conditions ranging from Alzheimer’s to cardiovascular disease.
What is proteomics?
Proteomics is the large-scale study of proteins, which are the functional molecules that link genetic information to physiological outcomes.
How does AI enhance proteomics?
Artificial intelligence analyzes complex protein data to identify patterns, improve biomarker discovery, and refine disease prediction models.